Literature DB >> 22109529

P-Rex1 is required for efficient melanoblast migration and melanoma metastasis.

Colin R Lindsay1, Samuel Lawn, Andrew D Campbell, William J Faller, Florian Rambow, Richard L Mort, Paul Timpson, Ang Li, Patrizia Cammareri, Rachel A Ridgway, Jennifer P Morton, Brendan Doyle, Shauna Hegarty, Mairin Rafferty, Ian G Murphy, Enda W McDermott, Kieran Sheahan, Katherine Pedone, Alexander J Finn, Pamela A Groben, Nancy E Thomas, Honglin Hao, Craig Carson, Jim C Norman, Laura M Machesky, William M Gallagher, Ian J Jackson, Leon Van Kempen, Friedrich Beermann, Channing Der, Lionel Larue, Heidi C Welch, Brad W Ozanne, Owen J Sansom.   

Abstract

Metastases are the major cause of death from melanoma, a skin cancer that has the fastest rising incidence of any malignancy in the Western world. Molecular pathways that drive melanoblast migration in development are believed to underpin the movement and ultimately the metastasis of melanoma. Here we show that mice lacking P-Rex1, a Rac-specific Rho GTPase guanine nucleotide exchange factor, have a melanoblast migration defect during development evidenced by a white belly. Moreover, these P-Rex1(-/-) mice are resistant to metastasis when crossed to a murine model of melanoma. Mechanistically, this is associated with P-Rex1 driving invasion in a Rac-dependent manner. P-Rex1 is elevated in the majority of human melanoma cell lines and tumour tissue. We conclude that P-Rex1 has an important role in melanoblast migration and cancer progression to metastasis in mice and humans.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22109529      PMCID: PMC3400057          DOI: 10.1038/ncomms1560

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  39 in total

1.  P-Rex1 participates in Neuregulin-ErbB signal transduction and its expression correlates with patient outcome in breast cancer.

Authors:  J C Montero; S Seoane; A Ocaña; A Pandiella
Journal:  Oncogene       Date:  2010-11-01       Impact factor: 9.867

2.  Inhibition of mutated, activated BRAF in metastatic melanoma.

Authors:  Keith T Flaherty; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Peter J O'Dwyer; Richard J Lee; Joseph F Grippo; Keith Nolop; Paul B Chapman
Journal:  N Engl J Med       Date:  2010-08-26       Impact factor: 91.245

3.  Identification of the Rac-GEF P-Rex1 as an essential mediator of ErbB signaling in breast cancer.

Authors:  Maria Soledad Sosa; Cynthia Lopez-Haber; Chengfeng Yang; Hongbin Wang; Mark A Lemmon; John M Busillo; Jiansong Luo; Jeffrey L Benovic; Andres Klein-Szanto; Hiroshi Yagi; J Silvio Gutkind; Ramon E Parsons; Marcelo G Kazanietz
Journal:  Mol Cell       Date:  2010-12-22       Impact factor: 17.970

4.  Embryonic signaling in melanoma: potential for diagnosis and therapy.

Authors:  Luigi Strizzi; Katharine M Hardy; Gina T Kirsammer; Pedram Gerami; Mary J C Hendrix
Journal:  Lab Invest       Date:  2011-04-04       Impact factor: 5.662

Review 5.  Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?

Authors:  Dominico Vigil; Jacqueline Cherfils; Kent L Rossman; Channing J Der
Journal:  Nat Rev Cancer       Date:  2010-11-24       Impact factor: 60.716

6.  Selective activation of Akt1 by mammalian target of rapamycin complex 2 regulates cancer cell migration, invasion, and metastasis.

Authors:  E K Kim; S J Yun; J M Ha; Y W Kim; I H Jin; J Yun; H K Shin; S H Song; J H Kim; J S Lee; C D Kim; S S Bae
Journal:  Oncogene       Date:  2011-02-21       Impact factor: 9.867

7.  Translating cancer research into targeted therapeutics.

Authors:  J S de Bono; Alan Ashworth
Journal:  Nature       Date:  2010-09-30       Impact factor: 49.962

8.  Genetically engineered models have advantages over xenografts for preclinical studies.

Authors:  Oren J Becher; Eric C Holland
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

9.  Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.

Authors:  Gideon Bollag; Peter Hirth; James Tsai; Jiazhong Zhang; Prabha N Ibrahim; Hanna Cho; Wayne Spevak; Chao Zhang; Ying Zhang; Gaston Habets; Elizabeth A Burton; Bernice Wong; Garson Tsang; Brian L West; Ben Powell; Rafe Shellooe; Adhirai Marimuthu; Hoa Nguyen; Kam Y J Zhang; Dean R Artis; Joseph Schlessinger; Fei Su; Brian Higgins; Raman Iyer; Kurt D'Andrea; Astrid Koehler; Michael Stumm; Paul S Lin; Richard J Lee; Joseph Grippo; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Paul B Chapman; Keith T Flaherty; Xiaowei Xu; Katherine L Nathanson; Keith Nolop
Journal:  Nature       Date:  2010-09-30       Impact factor: 49.962

10.  Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system.

Authors:  Heidi V N Küsters-Vandevelde; Annelies Klaasen; Benno Küsters; Patricia J T A Groenen; Ilse A C H van Engen-van Grunsven; Marcory R C F van Dijk; Guido Reifenberger; Pieter Wesseling; Willeke A M Blokx
Journal:  Acta Neuropathol       Date:  2010-03       Impact factor: 17.088

View more
  82 in total

1.  The effect of CXCL9 on the invasion ability of hepatocellular carcinoma through up-regulation of PREX2.

Authors:  Xiaoqin Lan; Fang Xiao; Qiang Ding; Jiqiao Liu; Jingmei Liu; Junhua Li; Jiong Zhang; De-An Tian
Journal:  J Mol Histol       Date:  2014-08-24       Impact factor: 2.611

2.  PtdIns(3,4,5)P3-dependent Rac Exchanger 1 (PREX1) Rac-Guanine Nucleotide Exchange Factor (GEF) Activity Promotes Breast Cancer Cell Proliferation and Tumor Growth via Activation of Extracellular Signal-regulated Kinase 1/2 (ERK1/2) Signaling.

Authors:  Heng-Jia Liu; Lisa M Ooms; Nuthasuda Srijakotre; Joey Man; Jessica Vieusseux; JoAnne E Waters; Yue Feng; Charles G Bailey; John E J Rasko; John T Price; Christina A Mitchell
Journal:  J Biol Chem       Date:  2016-06-29       Impact factor: 5.157

3.  The first DEP domain of the RhoGEF P-Rex1 autoinhibits activity and contributes to membrane binding.

Authors:  Sandeep K Ravala; Jesse B Hopkins; Caroline B Plescia; Samantha R Allgood; Madison A Kane; Jennifer N Cash; Robert V Stahelin; John J G Tesmer
Journal:  J Biol Chem       Date:  2020-07-13       Impact factor: 5.157

4.  Lack of APC somatic mutation is associated with early-onset colorectal cancer in African Americans.

Authors:  Rosa M Xicola; Zarko Manojlovic; Gaius J Augustus; Sonia S Kupfer; Rajyasree Emmadi; Victoria Alagiozian-Angelova; Tim Triche; Bodour Salhia; John Carpten; Xavier Llor; Nathan A Ellis
Journal:  Carcinogenesis       Date:  2018-12-13       Impact factor: 4.944

Review 5.  The Rac GTPase in Cancer: From Old Concepts to New Paradigms.

Authors:  Marcelo G Kazanietz; Maria J Caloca
Journal:  Cancer Res       Date:  2017-08-14       Impact factor: 12.701

Review 6.  Developments in preclinical cancer imaging: innovating the discovery of therapeutics.

Authors:  James R W Conway; Neil O Carragher; Paul Timpson
Journal:  Nat Rev Cancer       Date:  2014-04-17       Impact factor: 60.716

Review 7.  PI3K signaling in cancer: beyond AKT.

Authors:  Evan C Lien; Christian C Dibble; Alex Toker
Journal:  Curr Opin Cell Biol       Date:  2017-03-24       Impact factor: 8.382

8.  PTEN inhibits PREX2-catalyzed activation of RAC1 to restrain tumor cell invasion.

Authors:  Sarah M Mense; Douglas Barrows; Cindy Hodakoski; Nicole Steinbach; David Schoenfeld; William Su; Benjamin D Hopkins; Tao Su; Barry Fine; Hanina Hibshoosh; Ramon Parsons
Journal:  Sci Signal       Date:  2015-03-31       Impact factor: 8.192

9.  ERK/MAPK Signaling Drives Overexpression of the Rac-GEF, PREX1, in BRAF- and NRAS-Mutant Melanoma.

Authors:  Meagan B Ryan; Alexander J Finn; Katherine H Pedone; Nancy E Thomas; Channing J Der; Adrienne D Cox
Journal:  Mol Cancer Res       Date:  2016-07-14       Impact factor: 5.852

10.  RhoJ modulates melanoma invasion by altering actin cytoskeletal dynamics.

Authors:  Hsiang Ho; Amelia Soto Hopkin; Rubina Kapadia; Priya Vasudeva; Jonathan Schilling; Anand K Ganesan
Journal:  Pigment Cell Melanoma Res       Date:  2013-01-07       Impact factor: 4.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.